Ad is loading...
CELU
Price
$2.76
Change
-$0.09 (-3.16%)
Updated
Nov 22 closing price
FATE
Price
$2.29
Change
+$0.22 (+10.63%)
Updated
Nov 22 closing price
100 days until earnings call
Ad is loading...

CELU vs FATE

Header iconCELU vs FATE Comparison
Open Charts CELU vs FATEBanner chart's image
Celularity
Price$2.76
Change-$0.09 (-3.16%)
Volume$105.02K
CapitalizationN/A
Fate Therapeutics
Price$2.29
Change+$0.22 (+10.63%)
Volume$3.91M
CapitalizationN/A
CELU vs FATE Comparison Chart
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CELU vs. FATE commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a StrongSell and FATE is a StrongBuy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (CELU: $2.76 vs. FATE: $2.29)
Brand notoriety: CELU and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 8% vs. FATE: 186%
Market capitalization -- CELU: $60.73M vs. FATE: $260.82M
CELU [@Biotechnology] is valued at $60.73M. FATE’s [@Biotechnology] market capitalization is $260.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, CELU is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • CELU’s TA Score: 5 bullish, 5 bearish.
  • FATE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CELU.

Price Growth

CELU (@Biotechnology) experienced а +12.20% price change this week, while FATE (@Biotechnology) price change was +13.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

CELU is expected to report earnings on May 14, 2024.

FATE is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($261M) has a higher market cap than CELU($60.7M). CELU YTD gains are higher at: 11.560 vs. FATE (-38.770). CELU (-169.58M) and FATE (-177.57M) have comparable annual earnings (EBITDA) . FATE has more cash in the bank: 297M vs. CELU (211). CELU has less debt than FATE: CELU (61.1M) vs FATE (99M). CELU has higher revenues than FATE: CELU (14.8M) vs FATE (13.4M).
CELUFATECELU / FATE
Capitalization60.7M261M23%
EBITDA-169.58M-177.57M95%
Gain YTD11.560-38.770-30%
P/E RatioN/AN/A-
Revenue14.8M13.4M110%
Total Cash211297M0%
Total Debt61.1M99M62%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CELUFATE
RSI
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 20 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
64%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CELU
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYRIX53.940.83
+1.56%
Rydex Retailing Inv
RYPRX12.760.17
+1.35%
Royce Premier Invmt
UIEMX20.920.03
+0.14%
Victory Emerging Markets Institutional
NMMEX15.220.02
+0.13%
Northern Active M Emerging Market Equity
DISRX23.76N/A
N/A
BNY Mellon International Stock Fund I

CELU and

Correlation & Price change

A.I.dvisor tells us that CELU and NVCT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and NVCT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
-3.16%
NVCT - CELU
29%
Poorly correlated
+4.08%
FATE - CELU
27%
Poorly correlated
+10.63%
PRAX - CELU
27%
Poorly correlated
+1.97%
RNAC - CELU
26%
Poorly correlated
+13.54%
SAGE - CELU
26%
Poorly correlated
+6.60%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+10.63%
ALLO - FATE
55%
Loosely correlated
+4.74%
ABCL - FATE
54%
Loosely correlated
+1.47%
INZY - FATE
53%
Loosely correlated
+4.46%
NTLA - FATE
53%
Loosely correlated
+3.62%
BEAM - FATE
52%
Loosely correlated
+6.23%
More